Once-Daily Version of Arikace For CF Patients Could Be Viable, According To Study
Bacterial infections pose a major health risk in cystic fibrosis patents, which can lead to hospitalization and life-threatening health issues. As a result, the research community continues to focus on new therapies that effectively treat CF patients for common bacterial infections in the lungs while also facilitating patient compliance.